Drug Profile
AK 20
Alternative Names: AK20™Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Obio Pharmaceutical Holdings
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in China
- 18 Feb 2009 Preclinical trials in Non-alcoholic steatohepatitis in China (unspecified route)